Amesite Inc. (AMST) - Form 10-K Summary
Business Context and Reporting Period
Company: Amesite Inc.
Filing Type: Annual Report (Form 10-K)
Fiscal Year Ended: June 30, 2024
Business Overview: Amesite is an emerging growth company developing AI-driven solutions for higher education (Amesite Engage) and healthcare (NurseMagic). The company operates remotely with 9 full-time employees and 2 consultants as of June 30, 2024. It is listed on the Nasdaq Capital Market under the symbol AMST.
Key Financial Metrics
| Metric | Year Ended June 30, 2024 | Year Ended June 30, 2023 |
|---|---|---|
| Net Revenue | $166,881 | $845,009 |
| Net Loss | $(4,403,182) | $(4,153,303) |
| Loss Per Share (Basic & Diluted) | $(1.73) | $(1.68) |
| Cash and Cash Equivalents | $2,071,016 | $5,260,661 |
| Restricted Cash | $100,000 | $100,000 |
| Total Assets | $3,314,177 | $6,349,752 |
| Total Liabilities | $798,465 | $265,327 |
| Stockholders' Equity | $2,515,712 | $6,084,425 |
| Operating Cash Flow | $(2,813,779) | $(3,249,176) |
Note: The filing does not provide specific gross margin percentages or debt covenants. The company reported no interest expense for the year ended June 30, 2024.
Material Changes vs. Prior Period
- Revenue Decline: Net revenue decreased by approximately 80% (from $845,009 to $166,881). Management attributes this to a strategic pivot away from large, cash-upfront deals that struggled with administrative barriers, toward a larger client base with lower-risk, fee-per-course models.
- Expense Reduction: Total operating expenses decreased by $322,985 (from $5,069,517 to $4,746,532).
- Technology & Content Development: Decreased by $449,219 due to payroll and contractor savings.
- Sales & Marketing: Decreased by $289,278 due to reduced vendor costs.
- General & Administrative: Increased by $415,512, primarily driven by Board Compensation, partially offset by savings in legal, audit, and insurance.
- Liquidity Position: Cash and cash equivalents declined by approximately $3.19 million year-over-year, reflecting continued negative operating cash flows despite expense reductions.
- Stock Structure: A 1-for-12 reverse stock split was effective in February 2023; all share data is presented on a split-adjusted basis.
Outlook, Risks, and Management Commentary
Going Concern Warning: The company has concluded that there is substantial doubt about its ability to continue as a going concern. Management forecasts it may not have sufficient cash to maintain planned operations for the next twelve months. Plans to alleviate this include completing financing transactions (e.g., common stock offerings), but success is not assured.
Strategic Focus:
- Healthcare: Focusing on NurseMagic, an app for nurses and caregivers. The company has closed 5 pilot programs and aims to convert these to enterprise licenses. The app is currently not HIPAA compliant, posing significant regulatory risk.
- Higher Education: Shifting to a no-fee setup model for community colleges, charging based on registrations to reduce customer risk and accelerate adoption.
Key Risks:
- Regulatory Compliance: NurseMagic's lack of HIPAA compliance creates legal and reputational risks in healthcare settings.
- Customer Concentration: Five customers comprised approximately 97% of total revenue in 2024.
- Capital Needs: The company requires substantial additional funding to continue operations and may face dilution if equity financing is pursued.
- Competition: Intense competition in both online education and healthcare software markets.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to secure immediate financing to cover the projected cash burn rate.
- Revenue Sustainability: Assess the viability of the new "fee-per-course" model versus the previous large-deal model that drove 2023 revenue.
- HIPAA Compliance: Confirm the timeline and cost for achieving HIPAA compliance for the NurseMagic app, as this is critical for enterprise adoption in healthcare.
- Customer Concentration: Review the specific contracts with the top 5 customers representing 97% of revenue to assess churn risk.
- Board Compensation: Analyze the impact of the $900,000 stock-based compensation expense for board members on future cash flow and dilution.